In vivo and in situ evaluation of innovative approaches in dentin hypersensitivity treatment

BMC Oral Health

Table 9 Comparison of patent dentinal tubule surface area percentages between and within treatment groups after stage I and stage II

	Descriptive statistics	PRG	Embrace	Duraphat	p-value
Stage I	Mean [± SD] (%)	21.0^aA [± 2.7]	26.2^bA (± 4.5)	23.2^abA [± 5.4]	0.001*
Stage I	Median (Range) (%)	20.9 (16.8–25.3)	24.7 (20.1–36.2)	25.1 (14.2–29.9)	0.001*
Stage II	Mean [± SD] (%)	0.6^aB [± 0.5]	8.0^bB [± 2.5]	11.9^cB [± 3.1]	< 0.001*
Stage II	Median (Range) (%)	0.5 (0.0–1.5)	6.5 (5.3–13.0)	11.3 (6.9–17.2)
	p-value	< 0.001*	< 0.001*	< 0.001*

* Statistically Significant at p = 0.05
**Values are presented as mean [± SD] and median (range) percentages. Statistical significance for between-group comparisons (same row) was determined using Kruskal-Wallis test followed by Dunn’s post hoc test for pairwise comparisons. Within-group comparisons (same column) were analyzed using Friedman test followed by Dunn’s post hoc test for pairwise comparisons
***Different lowercase letters (a, b, c) denote significant differences between groups at each time point
****Different uppercase letters (A, B, C, D) denote significant differences within groups over time

ISSN: 1472-6831